The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE. THE INFORMATION IN THIS DOCUMENT MUST BE READ IN ...

Core Viewpoint - PAVmed has successfully closed financings that eliminate all previously outstanding convertible securities, significantly strengthening its balance sheet and capital structure [1] Financing Details - The Series D Preferred Stock offering generated $30 million in gross proceeds, with warrants for an additional $30 million contingent on a positive Medicare local coverage determination for the EsoGuard test [1] - A new senior secured note with a three-year maturity raised an additional $15 million [1] - The total net cash proceeds from these transactions amount to approximately $7.7 million, which will be used for general working capital [1] Capital Structure Improvement - The proceeds from the financings were utilized to redeem all outstanding Series C Convertible Preferred Stock and fully retire existing convertible debt [1] - Assuming the exercise of associated warrants and conversion of Series D Preferred Stock, the company could achieve a clean capital structure consisting entirely of common stock and long-term debt, adding approximately $37.7 million in cash to the balance sheet [1] Strategic Positioning - PAVmed's Chairman and CEO highlighted that this transaction is a transformative outcome aimed at fixing the legacy capital structure and unlocking the company's asset strength for shareholders [1] - The company is now positioned to pursue additional commercial opportunities and enhance long-term shareholder value, leveraging its subsidiaries, including Lucid Diagnostics and Veris Health [1]

Core Viewpoint - Senseonics Holdings, Inc. has received CE Mark approval for its Eversense 365 continuous glucose monitoring (CGM) system, expanding its market reach in Europe and targeting over 30 million diabetes patients [2][3]. Group 1: Product Overview - Eversense 365 is the world's first and only one-year CGM, approved by the US FDA in September 2024 and launched in October 2024 [2]. - The system is designed to provide continuous glucose monitoring for up to 365 days, significantly reducing the need for frequent sensor changes compared to traditional CGMs [6][8]. - Eversense 365 has been cleared as an integrated CGM (iCGM) system in the US, allowing it to work with compatible medical devices, including insulin pumps [4]. Group 2: Market Expansion - The approval of Eversense 365 in the EU is expected to contribute to top-line revenue growth as the company takes full ownership of all commercial activities for the product [3]. - The company plans to launch Eversense 365 in Germany, Italy, Spain, and Sweden in the coming months [2]. Group 3: Strategic Goals - The CEO of Senseonics highlighted that 2026 will be a pivotal year for the company, focusing on commercial progress in both the US and Europe, and the integration with Sequel's twiist™ Automated Insulin Delivery System [3]. - The expansion into the European market is part of a long-term growth strategy aimed at increasing the total addressable market for the company [3]. Group 4: Product Benefits - Eversense 365 offers several advantages, including reduced data interruptions, minimal sensor replacements, and improved comfort for users [6][7]. - The system provides reliable alerts and exceptional accuracy, enhancing the user experience and quality of life for diabetes patients [6][7].

Core Insights - Surface Solutions Group (SSG) is entering Costa Rica to establish a new operation focused on high-precision manufacturing for the international medical industry [1][4] Group 1: Investment and Operations - SSG plans a long-term investment exceeding $10 million for land acquisition and the construction of a dedicated facility [2] - Construction is set to begin in early 2026, with operations expected to start gradually in 2027 after equipment installation and validation procedures [3] Group 2: Job Creation and Local Impact - The new facility is anticipated to create 15 to 20 jobs, targeting roles such as automated equipment operators, engineers, and maintenance technicians [4] - SSG's investment is expected to enhance Costa Rica's life sciences sector, which is increasingly demanding advanced technical capabilities and regulatory compliance [4] Group 3: Strategic Importance - SSG views Costa Rica as a strategic location to be closer to key customers, enabling early collaboration on new developments and more agile scaling of coating technologies [5] - The country is recognized for its solid production environment and a skilled talent base familiar with medical device industry standards [5]

Inspire Medical Systems FY Conference Summary Company Overview - **Company**: Inspire Medical Systems (NYSE: INSP) - **Industry**: Medical Technology, specifically focused on sleep apnea treatment Key Points and Arguments Financial Performance - **Q4 and Full-Year Revenue**: Pre-announced revenue reflects continued growth and adoption of the Inspire 5 system, with guidance for 2026 indicating a revenue growth of **10%-11%** [2][28] - **2025 Revenue Projection**: Expected to be approximately **$912 million** [4] - **Initial Revenue Guidance for 2026**: Projected between **$1.003 billion** and **$1.013 billion**, excluding contributions from increased reimbursement [25] Product Development and Market Position - **Inspire 5 System Launch**: Successful launch with **100% physician training**, **95% contract execution**, and **90% center participation** in the SleepSync program [4] - **Patient Adoption**: Over **125,000 patients** treated with Inspire, indicating a significant under-penetrated market with potential for growth [5][18] - **Clinical Outcomes**: Improved device performance with **87% inspiratory phase overlap** and a **79% responder rate** in clinical studies [10][11] Technological Advancements - **Inspire 5 Features**: Incorporates a closed-loop stimulation system with an accelerometer for improved respiratory detection, reducing procedure time to **30-45 minutes** [6][10] - **Future Developments**: Inspire 6 will introduce auto sleep detection, enhancing patient experience by automating device activation [8][46] Reimbursement and Regulatory Challenges - **Reimbursement Code**: Inspire procedures are billed under code **64568**, which has been associated with a nearly **50% premium** compared to previous codes [30][31] - **Ongoing Reimbursement Discussions**: The company is actively working with agencies to clarify billing practices and ensure proper reimbursement for procedures [34][35] Market Strategy and Growth Drivers - **Direct-to-Consumer Efforts**: Increased marketing efforts to raise awareness about Inspire therapy, targeting patients who may benefit from the device [18][19] - **Utilization Focus**: Emphasis on improving patient throughput in existing centers rather than solely opening new centers [49] Safety and Patient Outcomes - **Device Safety**: Continuous improvement in device explant rates, now less than **1%**, and revision rates reduced from **10%** to **1-1.5%** [14] - **Long-term Benefits**: New data indicates cardiovascular benefits associated with Inspire therapy, enhancing its value proposition compared to traditional CPAP treatments [16][30] Leadership and Organizational Changes - **New CFO Appointment**: Matt Osberg appointed as CFO, bringing diverse experience to the company [24] Additional Important Insights - **GLP-1 Medications**: The rise of GLP-1 medications for weight management may create a tailwind for Inspire by increasing the number of patients eligible for treatment [41][42] - **Patient Engagement**: The company is focused on improving patient engagement and education to enhance treatment adherence and outcomes [12][49] This summary encapsulates the key points discussed during the Inspire Medical Systems FY Conference, highlighting the company's financial outlook, product advancements, market strategies, and ongoing challenges in the reimbursement landscape.

Core Insights - ENvue Medical has launched a new development program integrating its NanoVibronix technology to enhance comfort for patients using indwelling nasogastric (NG) tubes [1][2][3] - The program aims to address the discomfort commonly associated with prolonged use of NG tubes, which are essential in hospital care but often lead to nasal and throat discomfort [2][3] Company Overview - ENvue Medical, Inc. specializes in intelligent, non-invasive solutions for enteral care, operating in both clinical and home care settings [5] - The company is headquartered in Tyler, Texas, with research and development facilities in Tel-Aviv and Nesher, Israel [5] - ENvue Medical focuses on two main technology platforms: the ENvue™ Navigation Platform for minimally invasive feeding tube placement and the integration of vibration-based comfort technology [5] Technology and Development - The newly launched program is based on peer-reviewed clinical research showing that surface acoustic wave micro-vibration technology can reduce friction at the tube-tissue interface during NG tube use [2] - The initiative is exploratory and does not represent a commercial product launch or regulatory clearance, but aims to improve patient comfort and support the company's long-term strategy for enteral care [3] - The program will assess technical feasibility, clinical pathways, and regulatory considerations for incorporating vibration-based technology into ENvue's enteral ecosystem [3]

Core Viewpoint - Nortech Systems (NSYS) has appointed Andrew Walko as Senior Vice President of Global Operations, succeeding John Lindeen, who will retire in the first quarter of 2026 [1] Group 1: Leadership Changes - Andrew Walko will oversee the Company's global operations, which include facilities in the U.S., Mexico, and China [1] - Walko has a strong background in the medical device industry, having held executive roles at Sanuwave and Biomerics, as well as senior manufacturing operations positions at Minnetronix [1] Group 2: Responsibilities - In his new role, Walko will be responsible for managing the global supply chain, new product introductions, production planning, and ensuring on-time delivery [1]

Core Insights - Positron Corporation has raised $2.0 million by issuing 1,333,333 shares to support its growth initiatives and strategic objectives [1][2][3] Group 1: Financial and Strategic Developments - The capital raised will be utilized to accelerate commercial expansion, product development, regulatory activities, and entry into new markets [2] - The company aims to enhance its balance sheet to expand market presence and increase system placements, particularly in advanced cardiac PET imaging solutions [3] Group 2: Company Overview and Market Position - Positron Corporation specializes in developing and commercializing advanced PET and PET-CT imaging systems, providing integrated solutions for nuclear medicine healthcare providers [4][5] - The company focuses on cardiac PET imaging, which is recognized as the gold standard in cardiac diagnostics, enabling accurate diagnosis of coronary artery disease [5][6] - Positron's unique market position and innovative technologies are expected to facilitate the adoption of cardiac PET and support growth in the nuclear imaging market [6] Group 3: Partnerships and Future Directions - The company is committed to advancing cardiac and oncology PET modalities through collaboration with Shenyang Intelligent Nuclear Technology Co., a subsidiary of Neusoft Medical Systems [7]

Core Insights - Medtronic is being evaluated as a potential significant opportunity within the medical device sector, highlighting its strengths, challenges, and future potential [1] Group 1: Company Overview - Medtronic is featured in a discussion that aims to provide insights into its market trends and investment opportunities [1] Group 2: Analyst Perspectives - The analysis includes contributions from expert analysts who break down the company's performance and outlook [1]

Core Insights - CapsoVision, Inc. has received FDA 510(k) clearance for its AI-assisted module for CapsoCam Plus, marking a significant step towards commercialization in the U.S. [1] - The CapsoCam Plus system is designed for visualizing the small bowel mucosa to detect abnormalities in both adults and children aged two years and older, positioning it as a more advanced solution compared to competitors [2][4] - The company emphasizes its unique in-house AI capabilities and a cloud-based architecture that enhances efficiency, accuracy, and accessibility in gastrointestinal diagnostics [3] Company Overview - CapsoVision is focused on developing advanced imaging and AI-enabled solutions for gastrointestinal disease detection and diagnosis, with its flagship product being the CapsoCam Plus, a wire-free capsule endoscope [4] - The upcoming product, CapsoCam Colon, aims to enhance non-invasive colon imaging and polyp detection, indicating the company's commitment to expanding its product pipeline across various GI indications [4]